EFFORT Further Extension Study
Efficacy of Long-term Telbivudine Treatment on Histological Improvements in Patients With Chronic Hepatitis B (EFFORT Further Extension Study)
Sponsor: Major Science and Technology Special Project of China Twelfth-Five-Year Project
A PHASE4 clinical study on Hepatitis B, Chronic, this trial is ongoing. The trial is conducted by Major Science and Technology Special Project of China Twelfth-Five-Year Project and has accumulated 7 data snapshots since 2015. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
Jul 2023 — Jul 2024 [monthly]
Unknown Status PHASE4
-
Jan 2021 — Jul 2023 [monthly]
Unknown Status PHASE4
-
Jul 2018 — Jan 2021 [monthly]
Unknown Status PHASE4
Status: Active Not Recruiting → Unknown Status
▶ Show 2 earlier versions
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting PHASE4
-
Jan 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE4
First recorded
Apr 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Major Science and Technology Special Project of China Twelfth-Five-Year Project
- Nanfang Hospital, Southern Medical University
- Novartis
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beijing, China , Changchun, China , Changsha, China , Chongqing, China , Guangzhou, China , Hangzhou, China , Jinan, China , Nanjing, China , Shanghai, China , Shengyang, China and 2 more locations